Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

AbbVie stock jumped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

AbbVie (ABBV) stock hits all-time high after beating Q3 earnings expectations with newer immunology drugs outperforming ...

Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings ...

AbbVie Inc (ABBV) reports robust sales growth driven by Skyrizi and Rinvoq, raises full-year guidance, and announces a 5.8% ...

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.